Pratteln, Switzerland Tuesday, January 7, 2025, 11:00 Hrs [IST] ...
Santhera partners with Clinigen to supply Agamree for Duchenne muscular dystrophy in regions without commercial availability.
Santhera Pharmaceuticals (SIX: SANN) announces the signing of an exclusive agreement with Clinigen Group to manage the supply and distribution of AGAMREE® (vamorolone) ...
3d
Santhera Pharmaceuticals (SIX: SANN) announces the signing of an exclusive agreement with Clinigen Group to manage the supply and distribution of AGAMREE® (vamorolone) in countries where the product ...
Capricor Therapeutics has completed its US marketing application for deramiocel, a cell therapy the US biotech hopes will ...
Additionally, Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) launched Agamree (vamorolone) in 2024, an oral suspension for Duchenne Muscular Dystrophy (DMD), achieving strong initial commercial success.
Department of Health (DoH) of Hong Kong approved AGAMREE® for the treatment of Duchenne muscular dystrophy (DMD) inpatients aged 4 years and older Follows recent approval from China’s National Medical ...
Department of Health (DoH) of Hong Kong approved AGAMREE® for the treatment of Duchenne muscular dystrophy (DMD) inpatients aged 4 years and older Follows recent approval from China’s National ...
Pratteln, Switzerland, December 20, 2024 – Santhera Pharmaceuticals (SIX: SANN) announces that the Department of Health of Hong Kong, China, has approved AGAMREE® (vamorolone) for use in patients aged ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback